Investigational drug · Phase 3
NBI-1117568
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Schizophrenia, Bipolar I Disorder, Mania.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
6
Any phase or sponsor naming "NBI-1117568"
First trial start
2025
May 8, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NBI-1117568", any sponsor or status.
Conditions studied
As listed on its trial records.
- Schizophrenia
- Bipolar I Disorder
- Mania
Approved drugs for the same conditions: Schizophrenia · Bipolar disorder · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "NBI-1117568" as an intervention, largest first.
- NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With SchizophreniaPivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT07114874 · 600 participants (planned) · Start Jul 11, 2025 · Primary completion Dec 2031
Drug: NBI-1117568 · For: Schizophrenia
Sites: Bryant, Arkansas; Little Rock, Arkansas; Cerritos, California · 61 sites in all
- Efficacy of NBI-1117568 in Preventing Relapse in Adults With SchizophreniaPivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT07227818 · 560 participants (planned) · Start Dec 16, 2025 · Primary completion Jul 2029
Drug: NBI-1117568; Placebo · For: Schizophrenia
Sites: Garden Grove, California; La Habra, California; Lemon Grove, California · 25 sites in all
- NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaPivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT07105098 · 284 participants (planned) · Start Aug 11, 2025 · Primary completion Nov 2027
Drug: NBI-1117568; Placebo · For: Schizophrenia
Sites: Little Rock, Arkansas; Culver City, California; Garden Grove, California · 20 sites in all
- NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaPivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT06963034 · 284 participants (planned) · Start May 8, 2025 · Primary completion Oct 2027
Drug: NBI-1117568; Placebo · For: Schizophrenia
Sites: Bryant, Arkansas; Little Rock, Arkansas; Anaheim, California · 21 sites in all
- Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With SchizophreniaPivotal-lookingCompleted
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT05545111 · 210 participants · Start Oct 4, 2022 · Primary completion Jul 10, 2024
Drug: NBI-1117568; Placebo · For: Schizophrenia
Sites: Little Rock, Arkansas; Rogers, Arkansas; Lemon Grove, California · 15 sites in all
- An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current ManiaPivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT07288320 · 150 participants (planned) · Start Dec 24, 2025 · Primary completion Feb 2028
Drug: NBI-1117568; Placebo · For: Bipolar I Disorder; Mania
Sites: Little Rock, Arkansas; Cerritos, California; Garden Grove, California · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- New Pharmacological Treatment Approaches for Schizophrenia: Navigating the Post-iclepertin Landscape.
Englisch S, Zink M · CNS Drugs 2026
Also in development for Schizophrenia
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- SEP-363856UlotarontPhase 37 trials
Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder
- LB-102Phase 34 trials
LB Pharmaceuticals Inc. · Schizophrenia, Bipolar I Disorder
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- OLZSAM, ALKS 3831Phase 32 trials
Alkermes, Inc. · Bipolar I Disorder, Schizophrenia
- B2227Phase 31 trial
Bostal Drug Delivery Co., Ltd · Schizophrenia
- ML-007C-MAPhase 24 trials
MapLight Therapeutics · Psychosis Associated With Alzheimer's Disease, Schizophrenia
- ALTO-101Phase 21 trial
Alto Neuroscience · Schizophrenia, Cognitive Impairment
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Neurocrine Biosciences.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.